kstew call note think stock reaction
much call focus growth outlook margin
earn call finish littl bit ago raw note call first thought
stock coupl takeaw ay call
share versu believ reaction sigh relief regard
underlying/cor grow th rate past coupl quarter mix result think stock move bit over-
reaction one dive deeper number arent good headlin number suggest view
manag comment organ grow th like low end rang gross oper margin ere reduc
low er tax rate add per share full year yet overal ep guidanc rais midpoint net/net
noth chang view equal eight rate
organ growth quarter manag note organ grow th quarter legaci
vsi contribut point grow th there take vsi direct price standpoint includ
organ number also shift distributor order
organ growth rang re-affirmed low-end rang manag re-affirmed constant currenc grow th
rate ever organ grow th expect come low end hile contribut expect
come high end rang
organ growth bridg ytd full year manag highlight year-to-d organ grow th rate
see driver acceler first neotract ill anniversari expect add grow th second also
one addit ship day hich add expect grow th emea intervent access asia acceler
ad bring expect organ grow th low end rang
re-affirmed long-rang plan manag re-affirmed organ grow th guidanc hich incorpor vascular
solut neotract full year rate assum grow th legaci core also re-affirmed
tax rate reduct contribut year ep midpoint rais manag expect full year tax
rate versu prior guidanc rang includ greater benefit stock comp expens account
math add per share full year basi manag rais full year ep guidanc midpoint
manag reduc gross oper margin contribut
pleas feel free reach ith question im around
 raw note shorthand comment call apolog typo sale growth rate constant currenc
happi ith result quarter simpli rebound organ constant currenc also receiv
approv percuv phase safeti result repla acquir mantra tw scale acquisit vsi neotract
perform ell combin given confid achiev financi target outlin analyst day
may
result ere solid start year revenue report constant currenc basi driven continu
excel perform scale acquisit signific rebound organ revenu grow th hich includ
increas vsi product legaci line core product line deliv revenu grow th
continu level futur trace data reaffirm believ core busi perform ell
identifi event ere transient quarter prove case also identifi driver ould acceler
organ thank execut shift distributor order deliv organ revenu grow th expect
quarter organ grow th difficult comparison year organ revenu grow th focus
continu execut ytd perform give confid achiev albeit like low end
urolift strong momentum ith y/i impress intervent urolog team deliv hile overcom
suppli issu note call urolift suppli back
addit deliv strong top line get past suppli issu urolift subject sever medic confer
present quarter
vascular solut vsi revenu ere global grow th y/i vsi grow th robust na emea hich
continu benefit distributor convers anticip strong y/i revenu grow th
adjust gross oper respect restructur initi track
ep hich increas y/i despit fx rate less favor compar last guidanc rais ep guidanc
per share
revenu hich increas cc basi organ grow th ship day year ago
 organ hich legaci volum exclud surgic exit new product price offset
surgic exit neg acquisit contribut nearli hich neotract
addit color organ constant currenc revenu grow th acceler ytd rate driver first
 final quarter neotract buck ill start contribut organ expect add revenu
grow th also benefit one addit ship day quarter expect add expect grow th emea
intervent access asia acceler ad bring expect organ grow th low end
look longer term confid deliv cc revenu grow th neotract vascular solut help acceler
momentum grow th new product
includ vsi neotract pro forma grow th rate ytd
review quarter sale result
vascular na sale increas cc basi driven return distributor order picc ez-io
intervent na sale ere increas constant currenc basi driven higher sale vsi ell grow th
anesthesia na sale ere increas constant currenc basi grow th driven airw ay pain management product
surgic na sale revers neg trend increas constant currenc basi surgic driven instrument
sale eas suppli constraint partial off-set exit line expect surgic grow th rel flat vs
emea sale cc basi grow th larg driven distributor convers
asia increas grow th driven china revenu larg driven increas volum post go-direct
oem revenu cc basi increas due higher sale exist acceler time revenu
cc basi grow th attribut neotract lesser extent la
updat urolift
quarter subject studi present orld colleg urolog meet pari
 orld show ed clinic benefit qualiti life consist ith year lift studi
impact prostat size urolift improv symptom qol smaller larger
urolift use urinari retent men treat becam cathet free urolift
build larg bodi evid ith urolift product ith rate new onset sexual dysfunct
pleas announc yesterday receiv shonin approv japan estim market includ men ith
moder sever bph ho seen physician bph launch ill follow methodolog process establish
updat repla
complet phase safeti trial result present aabb octob trial random doubl blind dose
escal studi vs fresh frozen plasma data readout posit ell toler ith advers event safeti concern
expect submit bla earli
updat essenti medic
acquisit essenti medic obtain mantra devic larg bore arteriotomi ith sheath size procedur
associ ith tavr evar approv eu done procedur ytd believ larg unmet need larg
bore closur system manta could first us market show reduct complic rate versu sutur closur
estim tavr evar market opportun mantra
follow ing estim fda approv plan leverag call point intervent cardiologist
urolift urolift expect make signific grow th contribut
deploy sale market ezio on-control
vascular access picc grow th contributor expect market share gain futur ith uniqu coat
airw ay manag solut drive grow th
platform ic product turnpik traplin chocol balloon cathet expect chocol gener modest amount sale
excit repla percuv percuv receiv approv expect full market releas
increas invest support grow th period
given portfolio ell posit drive sustain constant currenc revenu grow th forese futur
gross profit margin expans reflect plan impact vsi neotract effici
favor price ever off-set unfavor product mix higher manufactur cost
oper profit y/i op margin dow decreas due tough prior year comp also shortfal gross
adjust interest expens year ago due addit borrow ing vsi neotract
tax rate versu year ago y/i declin impact tax reform tax indfal y/i
ep
ytd cfo dow y/i due unfavor chang off-set favor oper result
repaid debt leverag per rate agenc definit
cross currenc sw ap transact oct execut hedg variabl us/euro notion exchang ith interest
rate euro equival ith rate design net invest hedg expir
oct given differenti coupon rate euro-to-dollar exchang rate estim interest benefit
annual basi benefit ill help mitig impact rise interest rate environ variabl debt
revenu guidanc updat fx full year favor vs prior guidanc
reaffirm constant currenc revenu rang continu expect organ although expect
low end rang
constant currenc grow th driven contribut hich expect high end rang
adjust report revenu grow th
margin reflect ytd trend low ere gross margin expect adjust due
unfavor product mix oem busi modest dilut acquisit tariff china higher expens relat neotract
off-set half sg expens control thu oper margin guidanc reduc
interest expens expect interest expens reduct due cross currenc sw ap reduct
tax expect full year vs guidanc
bottom line rais outlook increas midpoint due over-perform vs
deliv solid cc organ revenu grow th pleas ith ep grow th ytd grow th disappoint need
adjust dow margin guidanc adjust gpm still increas mani issu transitori natur driver multi-year
expans plan track
vsi neotract vida care margin driver
 ith recent acquisit essenti medic add anoth high grow th potenti portfolio
multi-year financi plan includ littl contribut repla peruv could come multi-year
question answer question manag respons verbatim
year think organ revenu growth guidanc impli lrp next year
somewher midpoint rang guidanc ill provid februari right expect grow th
look quarter core urolift ill add addit day get increas perform
reaffirm cc guidanc
help us impact earn next year debt tax tariff etc think issu tariff next
year full year impact noth insurmount tax rate benefit improv rate vs prior year due tax cut
job act expect benefit continu due stock base indfal hich less predict peopl exercis
equiti predict right ould difficult tax front thing caus rate upper pressur
implement sw ap reduc interest put upper pressur mix littl us base expect tax rate
sure ill get level see year currenc headw ind right averag year probabl rel
euro rang could slight headw ind us there rest currenc
updat new product percuv repla also manta think contribut product
manta go pma approv north american market could goos laid golden egg need panel
review approv dont earlier year percuv market still global limit market releas late
 ill start roll ant access pent demand remov product market
place great start point get think manta ill address market opportun believ ill first
market ith product eve talk ith compani past year make decis hether buy
 ere ork intern product difficult get product larg bore ork think product make
cath lab effici
oem account chang contribut contempl guidanc quarter revenu put
take take account probabl posit net/net oem posit didnt get fulli suppli
disrupt add distributor order impact
gross margin direct next year fair issu ere transitori natur long term guidanc
ratabl noth chang restructur program noth chang ith vsi neotract item
impact major transitori tarrif sticki that look long term margin expans predic key
thing restructur program track deliv expect also margin expans base product offer
neotract vsi vida remain confid perform neotract beat expect vsi put doubl
digit grow th second quarter row expect continu expans next year come year
back inorgan item actual true organ growth ex vsi growth organ grow th
includ vsi therefor true organ basi there take vsi direct price standpoint includ
organ number
busi understand guy think manag busi mayb like
optim growth realli good enough grow th equal tri grow neotract intervent
access asia anesthesia busi one thing common accret gross margin busi look core
busi grew guidanc end year close core busi littl less
enough believ neotract vsi still comfort ith grow th lrp period
urolift happen push front line therapi posit us clinic outcom data
compel urinari retent data compel need get greater penetr ith urologist
picc growth around quarter coat picc regist china ork look forw ard
product market submiss thereaft month
day one addit day add ill number day urolift add
quarter
urolift new physician exist physician stand today train urologist north
america util averag procedur month highest adopt physician teen beyond
revenu come exist physician continu see util rate improv go deeper physician practic
competit environ urolift rezum treatment go bph patient reduct
cathet rate critic import men realli sure rezum target turp market take share
abl therapi think better solut
china busi growth last quarter start lap move direct
sale hat happen laps go-direct china hy step dow grow th
distributor stock got said distributor order stuck
anticip quarter
fx headwind point annual ep versu last quarter currenc overal still tailw ind use
reduc revenu impact earn also dilut recent acquisit
increment tariff reduc interest expens due sw ap also tax
gross margin expans restructur look program underw ay combin
restructur time complet realiz save ill
realiz year remaind think year
balanc thereaft compon gross margin signific compon biggest impact realli
mix favor neotract vsi picc vidacar restructur program compon
urolift view ill continu invest behind clinic data kick studi franc ill assist europ think
 robust clinic data paper present recent confer
variabl year feel variabl result think consist
full year basi consist perform averag constant currenc grow th made
manag chang appoint head north america dont give quarterli guidanc judg
area share win increas competit picc area vidacar continu perform ell that
convert market intervent busi ith vsi continu grow take care encourag hat asia
pacif see tougher econom volatil ithin emea price pressur market
vascular solut growth sustain vsi go-direct count hich larg portion
see turnpik drive grow th that grow ing rang traplin ell take share also launch new product
around guidew ire build momentum market place pleas ith vsi perform overal intervent
busi unit see nice uplift legaci product didnt build sale synergi model think get
mantra devic like old angios domest asp coupl hundr buck similar product
differ market segment ould attract significantli higher asp hen close today use closur devic high
rate advers event rel hat see think could make cath lab effici price ouldnt
issu
japan neotract invest japan ere contempl guidanc pleas ith quick turnaround shonin
approv
 compani activ look asset what view mantra great exampl met year ago
 atch gener interest intervent men health anesthesia surgic space leverag
low abil activ find right asset
chang tax rate basic benefit ep guidanc ye that right
guidanc reduc what drive chang conting consider payment continu
see adjust also impair charg quarter relat hot spur technolog restructur
program expens ere initi year
think dilut accret deal neotract suppos accret next year
essenti medic essenti medic expect dilut partial reflect full year guidanc
 ill give guidanc essenti februari depend need panel review earlier time ill
better guidanc expect essenti medic ill dilut accret thereaft neotract
 ell track deliv accret line ith prior guidanc
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
